MS
Michael Schmidt Guggenheim Latest Price Targets & Analyst Ratings
# | Stock | Price | Price Target |
Upside Downside | Rating | Date | |
---|---|---|---|---|---|---|---|
1 |
1
Immunome
IMNM
$853M
| $9.80 | $25 |
155%
upside
| Buy | 10 days ago |
|
2 |
2
ADC Therapeutics
ADCT
$382M
| $3.40 | $10 |
194%
upside
| Buy | 22 days ago |
|
3 |
3
Oric Pharmaceuticals
ORIC
$1.05B
| $10.77 | $18 |
67%
upside
| Buy | 22 days ago |
|
4 |
4
Compass Therapeutics
CMPX
$466M
| $3.37 | $12 |
256%
upside
| Buy | 23 days ago |
|
5 |
ONC
5
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.1B
| $318.73 | $365 |
15%
upside
| Buy | 28 days ago |
|
6 |
6
Arvinas
ARVN
$559M
| $7.61 | $15 |
97%
upside
| Buy | 28 days ago |
|
7 |
7
Tango Therapeutics
TNGX
$760M
| $6.83 | $10 |
46%
upside
| Buy | 29 days ago |
|
8 |
8
Cogent Biosciences
COGT
$1.81B
| $12.94 | $17 |
31%
upside
| Buy | 1 month ago |
|
9 |
9
Revolution Medicines
RVMD
$7.28B
| $38.95 | $80 |
105%
upside
| Buy | 2 months ago |
|
10 |
10
ArriVent BioPharma
AVBP
$792M
| $19.52 | $45 |
131%
upside
| Buy | 2 months ago |
|
11 |
11
UroGen Pharma
URGN
$870M
| $18.80 | $15 |
20%
downside
| Buy | 3 months ago |
|
12 |
12
Kymera Therapeutics
KYMR
$3.02B
| $42.20 | $52 |
23%
upside
| Buy | 3 months ago |
|
13 |
13
Relay Therapeutics
RLAY
$690M
| $4 | $10 |
150%
upside
| Buy | 4 months ago |
|
14 |
14
Syndax Pharmaceuticals
SNDX
$1.39B
| $16.19 | $32 |
98%
upside
| Buy | 4 months ago |
|
15 |
NBTX
15
Nanobiotix
NBTX
$411M
| $8.52 | $8 |
6%
downside
| Buy | 5 months ago |
|
16 |
16
Merus
MRUS
$5.01B
| $66.23 | $109 |
65%
upside
| Buy | 5 months ago |
|
17 |
17
Verastem
VSTM
$650M
| $10.56 | $14 |
33%
upside
| Buy | 5 months ago |
|
18 |
18
Incyte
INCY
$16.7B
| $85.44 | $92 |
8%
upside
| Neutral | 5 months ago |
|
19 |
19
Exelixis
EXEL
$10.1B
| $37.38 | $42 |
12%
upside
| Buy | 6 months ago |
|
20 |
20
Xencor
XNCR
$597M
| $8.37 | $34 |
306%
upside
| Buy | 1 year ago |
|
21 |
21
Erasca
ERAS
$420M
| $1.48 | $25 |
1,589%
upside
| Buy | 4 years ago |
|
22 |
22
Monte Rosa Therapeutics
GLUE
$303M
| $4.91 | $30 |
511%
upside
| Buy | 4 years ago |
|